NCT03174951View on ClinicalTrials.gov

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

March 10, 2017

Study Completion Date

June 20, 2017

Conditions
Recurrent Pregnancy Loss
Interventions
DRUG

IVIg

Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.

Trial Locations (1)

Unknown

Alzahra hospital, Tabriz

All Listed Sponsors
lead

Tabriz University of Medical Sciences

OTHER

NCT03174951 - Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss | Biotech Hunter | Biotech Hunter